Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

It was identified that the patient had a small tonsil tumor that a biopsy revealed to be HPV-positive squamous cell carcinoma. The patient met with the Johns Hopkins Head and Neck Cancer ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...

Researchers are developing the world’s first topical cream to prevent and treat skin cancer, especially for organ transplant ...

night kalyan matka chart Hengrui PD-1 has two new indications for non-small cell lung cancer and esophageal squamous cell carcinoma AbbVie's BTK inhibitor ABBV-105 has applied for clinical trials in ...